News Archive

  • Clinical Story: It Takes a World to Cure a Cancer

    When Robin was first diagnosed with acute myeloid leukemia in December 2011, she knew that it would be a long journey for her fight against this cancer.

  • Translational Research: Cellular Therapeutics

    While the graft-versus-tumor effect provided by the donor graft can be very powerful in controlling the disease, disease relapse is still the primary reason that patients do not do well after an allogeneic transplantation.

  • Bench to Bedside: Disruptive Innovation

    While allogeneic transplantation can be life saving for patients with hematologic malignancies, or inherited disorders such as several forms of immuno-deficiency, the transplant-related side effects and complications remain the biggest hurdles.

  • The Modern-Day Magic Missile: Arming the T-Cells with Cancer-Targeting Antibody

    When Kohler and Milstein developed hybridoma technology in 1975, a monoclonal antibody was thought to be the “Magic Bullet” to treat cancer since it can go directly to the targeted cancer cells.

  • Clinical Story: It Takes a Village to Cure a Cancer

    When someone has mycosis fungoides, malignant cells in the blood travel to the skin, causing lesions that appear as an itchy rash.

  • Cellular Therapeutics: Release the Power of Individual Cellular Component

    While the role for the individual cell population of the donor graft is not fully understood after allogeneic transplant, recent works in the field have yielded some interesting observations which may lead to advances in clinical care.

  • Precision Medicine: Applying Cutting-Edge Technology to Patient Care

    One of the challenges to monitor disease status in hematologic malignancies after a curative treatment such as transplant is the lack of a patient-specific and sensitive test.

  • A Non-Myeloablative Allogeneic Transplant Becomes the Ultimate ImmunoTherapy

    While the graft-versus-cancer effect is highly desirable after allogeneic transplant, the toxicities associated with high dose chemotherapy/radiation during the conditioning regimen have been a barrier.